Article
The pulmonary route as a way to drug repositioning in COVID-19 therapy
Registro en:
SARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021.
1773-2247
10.1016/j.jddst.2021.102430
Autor
Sarcinelli, MIchelle Alvares
Silva, Thalita Martins da
Silva, Andressa Daniele Artico
Patricio, Beatriz Ferreira de Carvalho
Paiva, Flávia Costa Mendes de
Lima, Raissa Santos de
Silva, Manuela Leal da
Rocha, Helvécio Vinícius Antunes
Resumen
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Introduction: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society’s
routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there
is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy
considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a
promising approach would be the pulmonary drug delivery.
Objective: Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing
clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary
administration.
Method: A integrative literature review was conducted between June and July 2020, by extracting the results
from Clinical Trials, PubMed, Web of Science and Science Direct databases.
Results: By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4
drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and
incentive in this field.
Conclusion: Even though the lung is a target that facilitates viral infection and replication, formulations for
pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that
the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the
appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary
delivery field.